APA (7th ed.) Citation

M, S., J, R., M, E., F, D., L, N., MV, K., . . . MA, M. (2024). Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial. Annals of the American Thoracic Society, 21(11), 1550. https://doi.org/10.1513/AnnalsATS.202402-201OC

Chicago Style (17th ed.) Citation

M, Stahl, et al. "Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial." Annals of the American Thoracic Society 21, no. 11 (2024): 1550. https://doi.org/10.1513/AnnalsATS.202402-201OC.

MLA (9th ed.) Citation

M, Stahl, et al. "Long-Term Impact of Lumacaftor/Ivacaftor Treatment on Cystic Fibrosis Disease Progression in Children 2-5 Years of Age Homozygous for F508del-CFTR: A Phase 2, Open-Label Clinical Trial." Annals of the American Thoracic Society, vol. 21, no. 11, 2024, p. 1550, https://doi.org/10.1513/AnnalsATS.202402-201OC.